Patients with advanced diseases such as tuberculosis, AIDS and cancer die of a condition known as cachexia, which is also known as the wasting syndrome since it causes extreme thinness

Erwin Wagner, of the Spanish National Cancer Research Centre in Madrid, and his colleagues found that in mice and patients with cancer-associated cachexia, white fat undergoes significant changes and turns into calorie-burning brown fat. The transformation leads to increased energy consumption and organ wasting.
The team also discovered that inflammation plays an important role in turning white fat into brown fat during cancer-associated cachexia, which suggests a potential therapeutic target. Indeed, anti-inflammatory therapies, including the nonsteroidal anti-inflammatory drug (NSAID) Sulindac, ameliorated the severity of cachexia in mice.
"Our data suggest that inhibition of the browning of white fat represents a promising approach to ameliorate the severity of cachexia in cancer patients," says Dr. Wagner. "In addition, identifying biomarkers of browning at early stages of cancer development could help to predict which patients are going to develop cachexia and are good candidates to benefit from a preventive treatment."
Source-Eurekalert